Checkpoint blockade accelerates a novel switch from an NKT-driven TNFα response toward a T cell driven IFN-γ response within the tumor microenvironment

Background The temporal response to checkpoint blockade (CB) is incompletely understood. Here, we profiled the tumor infiltrating lymphocyte (TIL) landscape in response to combination checkpoint blockade at two distinct timepoints of solid tumor growth.Methods C57BL/6 mice bearing subcutaneous MC38...

Full description

Bibliographic Details
Main Authors: Satoshi Nemoto, Ryosuke Nakagawa, Shota Aoyama, Patricio Perez-Villarroel, James J Mulé, Adam William Mailloux
Format: Article
Language:English
Published: BMJ Publishing Group 2021-06-01
Series:Journal for ImmunoTherapy of Cancer
Online Access:https://jitc.bmj.com/content/9/6/e002269.full
id doaj-3bdcda385f4b4ead87311eb3629b67a3
record_format Article
spelling doaj-3bdcda385f4b4ead87311eb3629b67a32021-08-01T11:30:48ZengBMJ Publishing GroupJournal for ImmunoTherapy of Cancer2051-14262021-06-019610.1136/jitc-2020-002269Checkpoint blockade accelerates a novel switch from an NKT-driven TNFα response toward a T cell driven IFN-γ response within the tumor microenvironmentSatoshi Nemoto0Ryosuke Nakagawa1Shota Aoyama2Patricio Perez-Villarroel3James J Mulé4Adam William Mailloux5Department of Immunology, Moffitt Cancer Center, Tampa, Florida, USADepartment of Immunology, Moffitt Cancer Center, Tampa, Florida, USADepartment of Immunology, Moffitt Cancer Center, Tampa, Florida, USADepartment of Immunology, Moffitt Cancer Center, Tampa, Florida, USADepartment of Immunology, Moffitt Cancer Center, Tampa, Florida, USADepartment of Microbiology and Immunology, University of Iowa, Carver College of Medicine, Iowa City, Iowa, USABackground The temporal response to checkpoint blockade (CB) is incompletely understood. Here, we profiled the tumor infiltrating lymphocyte (TIL) landscape in response to combination checkpoint blockade at two distinct timepoints of solid tumor growth.Methods C57BL/6 mice bearing subcutaneous MC38 tumors were treated with anti-PD-1 and/or anti-CTLA-4 antibodies. At 11 or 21 days, TIL phenotype and effector function were analyzed in excised tumor digests using high parameter flow cytometry. The contributions of major TIL populations toward overall response were then assessed using ex vivo cytotoxicity and in vivo tumor growth assays.Results The distribution and effector function among 37 distinct TIL populations shifted dramatically between early and late MC38 growth. At 11 days, the immune response was dominated by Tumor necrosis factor alpha (TNFα)-producing NKT, representing over half of all TIL. These were accompanied by modest frequencies of natural killer (NK), CD4+, or CD8+ T cells, producing low levels of IFN-γ. At 21 days, NKT populations were reduced to a combined 20% of TIL, giving way to increased NK, CD4+, and CD8+ T cells, with increased IFN-γ production. Treatment with CB accelerated this switch. At day 11, CB reduced NKT to less than 20% of all TIL, downregulated TNFα across NKT and CD4+ T cell populations, increased CD4+ and CD8+ TIL frequencies, and significantly upregulated IFN-γ production. Degranulation was largely associated with NK and NKT TIL. Blockade of H-2kb and/or CD1d during ex vivo cytotoxicity assays revealed NKT has limited direct cytotoxicity against parent MC38. However, forced CD1d overexpression in MC38 cells significantly diminished tumor growth, suggesting NKT TIL exerts indirect control over MC38 growth.Conclusions Despite an indirect benefit of early NKT activity, CB accelerates a switch from TNFα, NKT-driven immune response toward an IFN-γ driven CD4+/CD8+ T cell response in MC38 tumors. These results uncover a novel NKT/T cell switch that may be a key feature of CB response in CD1d+ tumors.https://jitc.bmj.com/content/9/6/e002269.full
collection DOAJ
language English
format Article
sources DOAJ
author Satoshi Nemoto
Ryosuke Nakagawa
Shota Aoyama
Patricio Perez-Villarroel
James J Mulé
Adam William Mailloux
spellingShingle Satoshi Nemoto
Ryosuke Nakagawa
Shota Aoyama
Patricio Perez-Villarroel
James J Mulé
Adam William Mailloux
Checkpoint blockade accelerates a novel switch from an NKT-driven TNFα response toward a T cell driven IFN-γ response within the tumor microenvironment
Journal for ImmunoTherapy of Cancer
author_facet Satoshi Nemoto
Ryosuke Nakagawa
Shota Aoyama
Patricio Perez-Villarroel
James J Mulé
Adam William Mailloux
author_sort Satoshi Nemoto
title Checkpoint blockade accelerates a novel switch from an NKT-driven TNFα response toward a T cell driven IFN-γ response within the tumor microenvironment
title_short Checkpoint blockade accelerates a novel switch from an NKT-driven TNFα response toward a T cell driven IFN-γ response within the tumor microenvironment
title_full Checkpoint blockade accelerates a novel switch from an NKT-driven TNFα response toward a T cell driven IFN-γ response within the tumor microenvironment
title_fullStr Checkpoint blockade accelerates a novel switch from an NKT-driven TNFα response toward a T cell driven IFN-γ response within the tumor microenvironment
title_full_unstemmed Checkpoint blockade accelerates a novel switch from an NKT-driven TNFα response toward a T cell driven IFN-γ response within the tumor microenvironment
title_sort checkpoint blockade accelerates a novel switch from an nkt-driven tnfα response toward a t cell driven ifn-γ response within the tumor microenvironment
publisher BMJ Publishing Group
series Journal for ImmunoTherapy of Cancer
issn 2051-1426
publishDate 2021-06-01
description Background The temporal response to checkpoint blockade (CB) is incompletely understood. Here, we profiled the tumor infiltrating lymphocyte (TIL) landscape in response to combination checkpoint blockade at two distinct timepoints of solid tumor growth.Methods C57BL/6 mice bearing subcutaneous MC38 tumors were treated with anti-PD-1 and/or anti-CTLA-4 antibodies. At 11 or 21 days, TIL phenotype and effector function were analyzed in excised tumor digests using high parameter flow cytometry. The contributions of major TIL populations toward overall response were then assessed using ex vivo cytotoxicity and in vivo tumor growth assays.Results The distribution and effector function among 37 distinct TIL populations shifted dramatically between early and late MC38 growth. At 11 days, the immune response was dominated by Tumor necrosis factor alpha (TNFα)-producing NKT, representing over half of all TIL. These were accompanied by modest frequencies of natural killer (NK), CD4+, or CD8+ T cells, producing low levels of IFN-γ. At 21 days, NKT populations were reduced to a combined 20% of TIL, giving way to increased NK, CD4+, and CD8+ T cells, with increased IFN-γ production. Treatment with CB accelerated this switch. At day 11, CB reduced NKT to less than 20% of all TIL, downregulated TNFα across NKT and CD4+ T cell populations, increased CD4+ and CD8+ TIL frequencies, and significantly upregulated IFN-γ production. Degranulation was largely associated with NK and NKT TIL. Blockade of H-2kb and/or CD1d during ex vivo cytotoxicity assays revealed NKT has limited direct cytotoxicity against parent MC38. However, forced CD1d overexpression in MC38 cells significantly diminished tumor growth, suggesting NKT TIL exerts indirect control over MC38 growth.Conclusions Despite an indirect benefit of early NKT activity, CB accelerates a switch from TNFα, NKT-driven immune response toward an IFN-γ driven CD4+/CD8+ T cell response in MC38 tumors. These results uncover a novel NKT/T cell switch that may be a key feature of CB response in CD1d+ tumors.
url https://jitc.bmj.com/content/9/6/e002269.full
work_keys_str_mv AT satoshinemoto checkpointblockadeacceleratesanovelswitchfromannktdriventnfaresponsetowardatcelldrivenifngresponsewithinthetumormicroenvironment
AT ryosukenakagawa checkpointblockadeacceleratesanovelswitchfromannktdriventnfaresponsetowardatcelldrivenifngresponsewithinthetumormicroenvironment
AT shotaaoyama checkpointblockadeacceleratesanovelswitchfromannktdriventnfaresponsetowardatcelldrivenifngresponsewithinthetumormicroenvironment
AT patricioperezvillarroel checkpointblockadeacceleratesanovelswitchfromannktdriventnfaresponsetowardatcelldrivenifngresponsewithinthetumormicroenvironment
AT jamesjmule checkpointblockadeacceleratesanovelswitchfromannktdriventnfaresponsetowardatcelldrivenifngresponsewithinthetumormicroenvironment
AT adamwilliammailloux checkpointblockadeacceleratesanovelswitchfromannktdriventnfaresponsetowardatcelldrivenifngresponsewithinthetumormicroenvironment
_version_ 1721245867889917952